

Applicants: Jeffrey Lynn Haddox, Roswell Robert Pfister,
James Edwin Blalock, and Matteo Villain
Serial No.: To be assigned
Filed: Herewith
Page 3

Please add new Claims 10 and 11 as follows:

af 10. (new) A pharmaceutical composition for ophthalmologic uses, comprising a complementary peptide having a sequence complementary to proline-glycine-proline (PGP) (SEQ ID NO:1), wherein said complementary peptide is selected from the group consisting of RTR (SEQ ID NO:2), RTRGG (SEQ ID NO:3), RTR dimer, RTR tetramer, RTR octamer, N-acetyl-RTR multimer, short-chain and long-chain fatty acid RTR multimer, RTR multimer using diaminopropionic acid for the core subunit, RTR multimer using diaminobutyric acid for the core subunit, RTR multimer containing a spacer having the formula $\text{NH}_2[\text{CH}_2]_n\text{-COOH}$ [$n=2[3\text{-aminopropionic acid}] \dots 7[8\text{-aminocaprylic acid}]$], said spacer replacing diglycine spacer, cysteine RTR multimer having a bicyclic structure, and XTR multimer with N-terminal modifications and core subunit modifications, wherein said complementary peptides have dextrorotatory amino acids substituting for the natural levorotatory, and wherein X may be any amino acid.

11. (new) A method of inhibiting polymorphonuclear leukocyte polarization, chemotaxis, and infiltration into tissue activated by a neutrophil chemoattractant in an individual, comprising the step of administering to said individual a pharmaceutical composition for ophthalmologic uses, so as to inhibit polymorphonuclear leukocyte infiltration into tissue, wherein said neutrophil chemoattractant is selected from the group consisting of N-acetyl-PGP, N-acetyl-PGX, N-methyl-PGX, N-methyl-PGP, and small peptide chemoattractants containing proline and glycine, wherein said pharmaceutical composition comprises a complementary peptide having a sequence complementary to proline-glycine-proline (PGP) (SEQ ID NO:1), and wherein X may be any amino acid.